Hematological malignacies
Conditions
Interventions
ABO matched:none
Minor incompatibility:none
Major incompatibility:none
Bidirectional incompatibility:none
Sponsors
The First Affiliated Hospital of Medical College of Zhejiang University
Eligibility
Sex/Gender
All
Age
10 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.The subjects or their legal representatives signed the informed consent before the clinical study. 2.Patients aged 10 to 70 years. 3.Patients with malignant hematological diseases plan to receive allogeneic peripheral blood stem cell transplantation 4.Patients have no suitable HLA identical sibling donor 5.Patients with malignant hematological diseases plan to receive HLA haploidentical stem cell transplantation 6.Patients with ECoG score of 0-2.
Exclusion criteria
Exclusion criteria: 1.Patients have suitable HLA identical sibling donor. 2.Patients with severe liver and kidney function (alanine aminotransferase > 2.5 times of the upper normal limit, serum creatinine > 1.5 times of the upper normal limit), cardiopulmonary dysfunction (cardiac function NYHA III / IV, cardiac ejection fraction < 50%, severe obstructive or restrictive ventilation dysfunction). 3.Patients with active infection. 4.Patients diagnosed with aplastic anemia before transplantation. 5.Patients with secondary tumor. 6.Patients who cannot independently choose to enter or exit clinical trials due to serious central nervous system disease or mental disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-relapse mortality;incidence of graft versus host disease; neutrophils engraftment;platelets engraftment;blood transfusion requirements;blood transfusion independence;the incidence of poor graft function;the incidence of graft failure; | — |
Countries
China
Contacts
Public ContactHuang He
The First Affiliated Hospital of Medical College of Zhejiang University
Outcome results
None listed